Slide 1: Second Quarter 2016 Earnings Teleconference
Second Quarter 2016 Earnings Teleconference August 2, 2016
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Second Quarter 2016 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Second Quarter 2016 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Strong Pfizer standalone financial performance in the first half of 2016 has been driven by new products in addition to patent protected products that are later in their life cycles, as well as operational growth in emerging markets We have evolved our operating model into two d
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Second Quarter 2016 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Second Quarter 2016 2015 Change Revenues $13,147 $11,853 11% Reported Net Income(1) 2,019 2,626 (23%) Reported Diluted EPS(1) 0.33 0.42 (21%) Adjusted Income(2) 3,901 3,525 11% Adjusted Diluted EPS(2) 0.64 0.56 14% Q2
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Second Quarter 2016 2015 FX Impact Revenues $13,147 $11,853 ($302) (3%) Adjusted Cost of Sales(1) 3,062 2,123 (191) (9%) Adjusted SI&A Expenses(1) 3,443 3,372 83
Slide 9: 2016 Financial Guidance
2016 Financial Guidance(1)(2) Revenues $51.0 to $53.0 billion Adjusted Cost of Sales(3) as a % of Revenues 21.0% to 22.0% Adjusted SI&A Expenses(3) $13.7 to $14.7 billion Adjusted R&D Expenses(3) $7.4 to $7.8 billion Adjusted Other (Income) / Deductions(3) Approximately ($500 million) of income Effe
Slide 10: Key Takeaways
Key Takeaways Achieved another strong quarter of Pfizer operational revenue growth, primarily driven by: A $1.1 billion contribution from the legacy Hospira business, as well as the solid performance of Ibrance, Eliquis, Xeljanz, & Lyrica Reaffirmed 2016 revenue and adjusted diluted EPS financial
Slide 11: Q&A Session
Second Quarter 2016 Earnings Teleconference Q&A Session August 2, 2016
Slide 12: Appendix: Segment Financial Highlights
Appendix Segment Financial Highlights August 2, 2016
Slide 13: Pfizer Innovative Health Selected Financial Highlights
Pfizer Innovative Health Selected Financial Highlights ($ Millions, Except Percentages) Second Quarter Q2 2016 revenues increased 9% operationally to $7,105M vs. Q2 2015 % Change 2016 2015 Driven by Ibrance in the U.S., Eliquis globally, and Total Oper. Lyrica and Xeljanz, both primarily in the
Slide 14: Pfizer Essential Health Selected Financial Highlights
Pfizer Essential Health Selected Financial Highlights ($ Millions, Except Percentages) Second Quarter Q2 2016 revenues increased 19% operationally to $6,042M vs. Q2 2015 % Change 2016 2015 Driven by the inclusion of legacy Hospira operations Total Oper. (HSP), which contributed $1.1B Revenues $6